Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

This study has been completed.
Sponsor:
Collaborator:
Southwestern Oncology Group (SWOG)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00077428
First received: February 10, 2004
Last updated: January 23, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)